Pediatrix Medical Group, Inc. (MD)
NYSE: MD · Real-Time Price · USD
24.65
+0.82 (3.44%)
At close: Nov 25, 2025, 4:00 PM EST
24.65
0.00 (0.00%)
After-hours: Nov 25, 2025, 4:10 PM EST
Pediatrix Medical Group Stock Forecast
Stock Price Forecast
The 4 analysts that cover Pediatrix Medical Group stock have a consensus rating of "Hold" and an average price target of $21, which forecasts a -14.81% decrease in the stock price over the next year. The lowest target is $17 and the highest is $24.
Price Target: $21 (-14.81%)
Analyst Consensus: Hold
Analyst Ratings
The average analyst rating for Pediatrix Medical Group stock is "Hold". This means that analysts believe this stock is likely to perform similarly to the overall market.
Recommendation Trends
| Rating | Jun '25 | Jul '25 | Aug '25 | Sep '25 | Oct '25 | Nov '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 1 | 0 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 4 | 4 | 4 | 5 | 5 | 3 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 6 | 6 | 6 | 7 | 7 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Truist Securities | Truist Securities | Hold Maintains $17 → $24 | Hold | Maintains | $17 → $24 | -2.64% | Nov 10, 2025 |
| UBS | UBS | Hold Maintains $17 → $23 | Hold | Maintains | $17 → $23 | -6.69% | Nov 5, 2025 |
| Leerink Partners | Leerink Partners | Hold Maintains $15 → $17 | Hold | Maintains | $15 → $17 | -31.03% | Sep 5, 2025 |
| UBS | UBS | Hold Maintains $16 → $17 | Hold | Maintains | $16 → $17 | -33.06% | Aug 14, 2025 |
| UBS | UBS | Hold Maintains $19 → $16 | Hold | Maintains | $19 → $16 | -35.09% | May 12, 2025 |
Financial Forecast
Revenue This Year
1.94B
from 2.01B
Decreased by -3.52%
Revenue Next Year
2.00B
from 1.94B
Increased by 2.73%
EPS This Year
1.85
from -1.19
EPS Next Year
1.89
from 1.85
Increased by 2.15%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 2.1B | 2.1B | |||
| Avg | 1.9B | 2.0B | |||
| Low | 1.8B | 1.8B |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 2.3% | 9.6% | |||
| Avg | -3.5% | 2.7% | |||
| Low | -9.7% | -6.3% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 1.92 | 2.03 | |||
| Avg | 1.85 | 1.89 | |||
| Low | 1.72 | 1.68 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | 9.7% | |||
| Avg | - | 2.2% | |||
| Low | - | -9.3% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.